New vaccine aims to stop multiple myeloma from coming back
NCT ID NCT06435910
First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times
Summary
This early-stage trial tests a personalized dendritic cell vaccine in 10 multiple myeloma patients who are already in very good remission. The vaccine is designed to train the immune system to keep the cancer from returning. The main goal is to see if the vaccine is safe, with a secondary look at whether it helps maintain remission.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dendritic cell vaccine
- What this could lead to
- If it works, this could help multiple myeloma patients stay in remission longer after standard treatment.
- What could go wrong
- This is a very early Phase 1 trial with only 10 participants, so it is too soon to know if it works. The main goal is safety, not effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male and female subjects with multiple myeloma or plasmacytoma * Very good partial or complete remission (CR) after prior combination therapies. * Expected survival \> 12 weeks * Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal * Voluntary informed consent is given with willingness to continue follow up Exclusion Criteria: * Pregnant or lactating women * Uncontrolled active infection * HIV or active hepatitis B or hepatitis C infection * Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple myeloma or plasmacytoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.